Analysts Projecting Steady Growth for Accelerate Diagnostics, Inc. (NASDAQ:AXDX)

Analysts are projecting Accelerate Diagnostics, Inc. (NASDAQ:AXDX) to grow at an accelerated rate over the next five years.  Sell-side analysts are looking for the company to grow -3.80% over the next year and 30.00% over the next five years.

EPS measures what each share is worth and also indicates how much money their sharehoders would gain if the company was to pay out all of its profits.  Earnings Per Share is computed by dividing the total profit by its total shares.  If a company’s profit is $800 million and there are 40 million shares, then the EPS is $20.  EPS is a great way to compare and contrast companies from the same industry.  When a company shows a steady rising earnings trend, this indicates that the firm will have an advantage over companies with a more volatile earnings trend.  Accelerate Diagnostics, Inc.’s trailing 12- months EPS is -1.18.  Last year, their EPS growth was -42.60% and their EPS growth over the past five years was 19.36%.  


Let’s start off by taking a look at how the stock has been performing recently.  Over the past twelve months, Accelerate Diagnostics, Inc. (NASDAQ:AXDX)’s stock was 14.70%.  Last week, it was -10.04%, 27.06% over the last quarter, and  90.05% for the past half-year. 

Over the past 50 days, Accelerate Diagnostics, Inc. stock was -13.51% off of the high and 22.64% removed from the low.  Their 52-Week High and Low are noted here.  -13.51% (High), 139.55%, (Low). 


Accelerate Diagnostics, Inc. (NASDAQ:AXDX)’s performance this year to date is 14.70%.  The stock has performed -10.04% over the last seven days, -9.38% over the last thirty, and 27.06% over the last three months.  Over the last six months, Accelerate Diagnostics, Inc.’s stock has been 90.05% and 47.16% for the year.


Wall Street analysts are have a consensus analyst recommendation of 1.50 on the stock.  This is based on a 1-5 scale where 1 represents a Strong Buy and 5 a Strong Sell.  Brokerages covering the name have a $27.50 on the stock.

The advice provided on this website is general advice only. It has been prepared without taking into account your objectives, financial situation or needs. Before acting on this advice you should consider the appropriateness of the advice, having regard to your own objectives, financial situation and needs.  Where quoted, past performance is not indicative of future performance.

Leave a Comment